---

BRONCHIECTASIS — Comprehensive A2 Answer

---

1. INTRODUCTION & DEFINITION

• Chronic productive cough
• Daily sputum production
• Recurrent respiratory tract infections/exacerbations

• Prevalence: 52–139 cases/100,000 in the USA (increasing by ~8.7%/year)
• Total US cases estimated >110,000
• More common in women (1.3–1.6× higher) and Asians (2.5–3.9× higher vs. Caucasians/African Americans)
• Prevalence increases with age
• European data show incidence and point prevalence rising yearly from 2004–2013
• Significant economic burden: increased hospitalization vs. age-matched controls
• Associated with impaired QoL and mortality (influenced by sputum volume, airflow obstruction severity, chronic gram-negative infection — especially P. aeruginosa)

---

2. ETIOLOGY

A. Focal Bronchiectasis (localized)

• Bronchial obstruction — extrinsic (lymphadenopathy, tumor compression) or intrinsic (endobronchial tumor, aspirated foreign body, scarring/stenosis, bronchial atresia)

B. Diffuse Bronchiectasis (bilateral/widespread)

• Upper lobe: CF, ABPA, post-TB
• Lower lobe: Post-infectious, aspiration, immune deficiency
• Middle lobe/lingula (Lady Windermere pattern): NTM infection (MAC)
• Central: ABPA

---

3. PATHOGENESIS

Cole's "Vicious Cycle" Hypothesis (Key Framework)

Initial insult → Neutrophilic airway inflammation → Airway destruction in susceptible individuals → Anatomic disruption → Abnormal mucus clearance → Chronic bacterial infection → Further airway inflammation → Perpetuating cycle

1. Initial insult (infection, obstruction, inflammation) damages ciliated airway epithelium
2. Bacteria form biofilms; glycoproteins and IL-8 drive neutrophil recruitment
3. Human Neutrophil Elastase (HNE) — a key proteolytic enzyme — cleaves bronchial wall structural proteins (elastin, collagen, smooth muscle)
4. Reactive oxygen species and proinflammatory cytokines (TNF-α, IL-1β) amplify destruction
5. Goblet cell hyperplasia → excess mucus production
6. Impaired mucociliary clearance → mucus stasis → bacterial colonization
7. Loss of elastin and smooth muscle → permanent airway dilation
8. Smaller bronchioles become obliterated by fibrosis (bronchiolitis obliterans)
9. Antiproteases (α1-antitrypsin) are overwhelmed — hence α1-AT deficiency worsens the process

---

4. PATHOLOGY

Gross Pathology

• Dilated, thick-walled bronchi extending to the lung periphery (normally bronchi do not extend within 1 cm of pleura)
• Airways may be filled with mucopurulent secretions
• Surrounding lung parenchyma: fibrosis, consolidation, and collapse (atelectasis) — especially lower lobes
• In severe disease: lung abscess formation

Microscopic Pathology

1. Transmural inflammation — chronic inflammatory cell infiltrate in all layers of the bronchial wall
2. Destruction of smooth muscle and elastic tissue — hallmark of irreversibility
3. Goblet cell hyperplasia and mucous gland hypertrophy
4. Squamous metaplasia of bronchial epithelium
5. Fibrosis of bronchial wall and peribronchial tissue
6. Bronchiolitis obliterans in small airways
7. Neovascularization — bronchial arteries hypertrophy (source of hemoptysis)
8. Mucous plugging in smaller airways
9. Surrounding alveoli: pneumonia, fibrosis, and emphysema

• Bronchial obstruction → mucus plugging + infection → airway damage
• Bronchial wall damage → direct infection/inflammation
• Parenchymal fibrosis → traction bronchiectasis

---

5. CLASSIFICATION

A. Morphological Classification (Reid, 1950; most widely used on HRCT)

B. Anatomical Distribution

• Focal — single lobe/segment (usually obstructive cause)
• Multifocal — multiple lobes
• Diffuse — bilateral widespread (systemic cause)

C. Etiological Classification

• CF-related bronchiectasis
• Non-CF bronchiectasis (the broader clinical entity, focus of ERS 2025 guidelines)

D. By Bronchial Distribution (Anatomy)

• Upper lobe (ABPA, CF, post-TB)
• Lower lobe (post-infectious, aspiration)
• Middle lobe / lingula (NTM)
• Right middle lobe syndrome (specific entity)

---

6. PATHOPHYSIOLOGY

Pulmonary Function

• Obstructive ventilatory defect predominates (reduced FEV1/FVC)
• Increased RV and TLC (air trapping)
• Reduced DLCO in advanced disease
• The obstructive defect is primarily due to obliterative bronchiolitis (small airway disease), NOT large airway collapse or mucus plugging
• Mixed obstructive-restrictive pattern in fibrotic cases

Gas Exchange

• V/Q mismatch → hypoxemia
• Chronic hypoxemia → pulmonary vasoconstriction → pulmonary hypertension
• Cor pulmonale in advanced disease

Mucociliary Dysfunction

• Impaired cilia → mucus stasis → promotes colonization
• Daily mucus production >30 mL/day

Hemoptysis Mechanism

• Hypertrophied bronchial arteries (neovascularization at inflammation sites)
• Erosion of superficial mucosal vessels by recurrent infection
• Massive hemoptysis: life-threatening (>200–300 mL/24h)

Systemic Effects

• Chronic inflammatory state → cachexia, weight loss
• Amyloidosis (rare, secondary AA)
• Metastatic abscess (brain) — rare

---

7. CLINICAL FEATURES

Symptoms

Physical Examination

Exacerbation Features

• Increased sputum volume and purulence
• Worsening dyspnea
• New or increased hemoptysis
• Fever ± new infiltrate
• May NOT have fever/infiltrate (unlike pneumonia)

---

8. DIAGNOSIS

Clinical Diagnostic Criteria (International Expert Consensus)

1. Inner or outer airway-artery diameter ratio ≥1.5
2. Lack of airway tapering
3. Visibility of airways in the periphery (within 1 cm of pleura)

1. Cough most days of the week
2. Sputum production most days of the week
3. History of exacerbations

Chest X-Ray Findings

• Increased bronchial wall thickening — "tram-tracks" (dilated airways en face)
• Ring shadows (dilated airways seen end-on)
• "Tubular shadows" or "gloved finger" opacities (mucus-filled bronchi)
• Multiple thin-walled ring shadows with air-fluid levels (cystic)
• Volume loss/atelectasis in affected lobes
• Overinflation (generalized disease/CF)
• Poor sensitivity; may be normal in mild disease

Sputum Microbiology

• Haemophilus influenzae (most common colonizer)
• Pseudomonas aeruginosa (key prognostic organism; associated with accelerated decline)
• Staphylococcus aureus (CF especially)
• Moraxella catarrhalis
• Streptococcus pneumoniae
• Nontuberculous mycobacteria (NTM) — MAC most common
• Culture for AFB and fungi in appropriate clinical contexts

Pulmonary Function Tests

• FEV1/FVC: obstructive pattern
• ± Mixed pattern
• Baseline PFTs and serial monitoring recommended

Additional Investigations for Underlying Cause

---

9. HRCT FINDINGS

Primary HRCT Signs

CT Morphological Types

Additional/Associated HRCT Findings

CT Distribution Clues to Etiology

• Bilateral upper lobe → CF, ABPA, post-TB
• Bilateral lower lobe → Post-infectious, aspiration, immunodeficiency
• Central/proximal bronchi → ABPA (pathognomonic central bronchiectasis with mucoid impaction)
• Right middle lobe + lingula ("Lady Windermere") → NTM (MAC)

CT-Based Scoring Systems

• Bhalla score — severity scoring based on number of bronchopulmonary segments involved
• Reiff score — number of segments affected + type (cylindrical = 1, varicose = 2, cystic = 3)

---

---

10. TREATMENT

---

A. AIRWAY CLEARANCE TECHNIQUES (ACT) — ERS 2025: Strong Recommendation

• Chest physiotherapy (CPT) — postural drainage, manual percussion — cornerstone
• Active Cycle of Breathing Technique (ACBT)
• Oscillatory Positive Expiratory Pressure (OPEP) devices: Flutter valve, Acapella, RC-Cornet
• High-Frequency Chest Wall Oscillation (HFCWO) vest
• Minimum: 2×/day; individualized to disease severity
• Goal: clear secretions, reduce bacterial load, break vicious cycle

B. MUCOACTIVE AGENTS

C. BRONCHODILATORS

• Inhaled beta-2 agonists improve mucociliary clearance and reverse bronchoconstriction
• No strong RCT evidence in non-CF bronchiectasis; used by analogy and clinical benefit

D. ANTIBIOTIC THERAPY

1. Acute Exacerbations

• Duration: 14 days (minimum 7–10 days)
• Oral therapy (mild-moderate exacerbations):
  • Amoxicillin-clavulanate 625 mg TDS (H. influenzae, S. pneumoniae, M. catarrhalis)
  • Ciprofloxacin 500–750 mg BD (Pseudomonas aeruginosa or gram-negatives)
  • Azithromycin 500 mg OD × 3 days (alternative)
  • Levofloxacin 500–750 mg OD
  • Doxycycline 100 mg BD
• IV therapy (severe exacerbations / Pseudomonas):
  • Piperacillin-tazobactam 4.5 g TID IV
  • Ceftazidime 2 g TID IV
  • Meropenem 1 g TID IV
  • Ciprofloxacin 400 mg BD IV ± aminoglycoside (gentamicin 5–7 mg/kg OD IV)
  • Tobramycin 5–7 mg/kg OD IV (with level monitoring)
  • Colistin (polymyxin E) 2–3 MU TID IV (MDR Pseudomonas)

2. Long-Term/Chronic Oral Antibiotic Therapy (LTAT)

• Screen for NTM before starting (NTM growth → macrolide resistance)
• Baseline audiology and ECG (QTc prolongation risk)
• ERS 2025: Against routine use in patients with NTM due to risk of macrolide-resistant NTM

3. Long-Term Inhaled Antibiotic Therapy — ERS 2025: Strong Recommendation (chronic P. aeruginosa, high-risk)

4. Pseudomonas Eradication Treatment — ERS 2025: Conditional Recommendation

• Goal: eradicate new P. aeruginosa culture positivity before chronic colonization established
• Ciprofloxacin 500–750 mg BD oral × 3 weeks, PLUS
• Tobramycin 300 mg BD nebulized × 28 days
• OR Colistimethate nebulized
• Systematic review (PMID 38296344): benefit shown in CF; limited non-CF RCT data

5. NTM Treatment (MAC)

• Confirmed MAC lung disease (ATS criteria): ≥2 positive sputum cultures or 1 BAL positive
• Macrolide-based triple therapy: Azithromycin 500–600 mg 3×/week (or clarithromycin 1000 mg/day) + Rifampicin 600 mg/day + Ethambutol 15 mg/kg/day
• Duration: 12 months culture-negative (typically 18–24 months total)

E. INHALED CORTICOSTEROIDS — ERS 2025: Suggest Against Routine Use

• No significant benefit on exacerbation rate or lung function in non-CF bronchiectasis
• Risk: increased risk of NTM infection, local adverse effects
• Exception: Use if concurrent asthma or COPD indication

F. ORAL/SYSTEMIC CORTICOSTEROIDS

• Not recommended routinely in infectious bronchiectasis
• Indicated in ABPA: Prednisolone 0.5–1 mg/kg/day → taper over months
• ABPA + itraconazole: Itraconazole 200 mg BD × 16 weeks (reduces steroid requirement, reduces Aspergillus load)
• Active autoimmune cause (RA, Sjögren's): systemic immunosuppression per underlying disease

G. PULMONARY REHABILITATION — ERS 2025: Strong Recommendation (impaired exercise capacity)

• Supervised exercise training + education
• Duration: minimum 8 weeks (ideally 12–20 weeks)
• Improves exercise capacity (6MWD), QoL, dyspnea scores
• Combines aerobic, resistance, and breathing training

H. OXYGEN THERAPY

• Long-term oxygen therapy (LTOT) if resting SpO2 ≤88% on 2+ assessments
• Target SpO2 88–92% in those with CO2 retention risk

I. MANAGING COMPLICATIONS

1. Stabilize — airway protection; selective intubation of non-bleeding lung if needed
2. Identify source — rigid bronchoscopy
3. Bronchial Artery Embolization (BAE) — first-line interventional treatment (hypertrophied bronchial arteries); ~80% success
4. Surgical resection — if BAE fails or focal disease
5. Tranexamic acid 500–1000 mg IV/oral (adjunct)

• Combination antibiotics may be necessary
• Antibiotic cycling strategy (rotating inhaled antibiotics)

• Lung transplantation — consideration for CF and non-CF bronchiectasis with FEV1 <30%, rapid decline, increasing hospitalizations

J. SURGICAL TREATMENT

• Indications: Focal, drug-resistant disease; massive hemoptysis not controlled by BAE; resectable suppurative locus
• Procedure: Segmentectomy or lobectomy
• Rarely curative in diffuse disease

K. VACCINATION

• Annual influenza vaccine
• Pneumococcal vaccine (PCV13 + PPSV23 schedule)
• COVID-19 booster vaccination

---

11. NEWER / EMERGING THERAPIES

---

12. SEVERITY SCORING & PROGNOSTIC TOOLS

---

13. ERS 2025 GUIDELINE SUMMARY (Chalmers et al., PMID 41016738)

---

14. KEY ORGANISMS, BUGS, AND DRUG DOSES (Quick Reference Table)

---

Summary Schematic

BRONCHIECTASIS
│
├── ETIOLOGY: Post-infectious | CF/PCD/genetic | Immune deficiency | 
│            Autoimmune | ABPA | Obstruction | Idiopathic (50%)
│
├── PATHOGENESIS: Vicious cycle (Cole)
│   Initial insult → Neutrophil elastase + HNE + cytokines 
│   → Wall destruction → Mucostasis → Chronic infection → ↑ inflammation
│
├── PATHOLOGY: Dilated thick-walled bronchi, smooth muscle/elastic loss,
│             goblet cell hyperplasia, fibrosis, neovascularization
│
├── HRCT: Signet-ring sign, tram-tracks, lack of tapering, 
│         peripheral airways visible, tree-in-bud, mosaic attenuation
│
├── CLASSIFICATION: Cylindrical > Varicose > Cystic
│
├── CLINICAL: Productive cough, purulent sputum, hemoptysis,
│             crackles, clubbing, recurrent infections
│
└── TREATMENT:
    ├── ACT (Strong) + Pulmonary Rehab (Strong)
    ├── Antibiotics: Acute (14d) → Exacerbation-directed
    ├── Long-term macrolide (Strong) → Azithromycin 250mg OD
    ├── Inhaled antibiotics if chronic PA (Strong) → Tobramycin/Colistin
    ├── Mucoactives: Hypertonic saline, Mannitol (Conditional)
    ├── No ICS routinely (ERS 2025)
    ├── Newer: Brensocatib (DPP1 inhibitor) – most promising
    └── CF: CFTR modulators (Trikafta) – transformative

---

• Fishman's Pulmonary Diseases and Disorders, 2-Volume Set — Chapter 51 (Gregory Tino)
• Harrison's Principles of Internal Medicine 22E (2025) — Chapter 301 (Baron et al.)
• Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set
• Robbins, Cotran & Kumar: Pathologic Basis of Disease — Chapter 15
• Grainger & Allison's Diagnostic Radiology — Chapter 6
• ERS Clinical Practice Guideline for Adult Bronchiectasis 2025 — Chalmers JD et al. Eur Respir J 2025 (PMID 41016738)
• Pseudomonas Eradication Meta-Analysis — Conceição M et al. Eur Respir Rev 2024 (PMID 38296344)